EUVIMEDObjevte EUVIMED
Systematische ÜbersichtMetaanalyse

ELAMIPRETIDE AND CHRONIC FATIGUE SYMPTOMS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF TRIALS IN MITOCHONDRIAL DISEASES AND ITS TRANSLATIONAL RELEVANCE TO CHRONIC FATIGUE SYNDROME AND RELATED DISORDERS

Luiz Felippe Mendes Caquetti

INTERNATIONAL BLEST SCIENTIFIC · 2026-05-12 · 1 (03)

DOI: 10.65671/ft79c689 ↗

At a glance

Systematische Übersicht in INTERNATIONAL BLEST SCIENTIFIC, published online on 2026-05-12. Written by Luiz Felippe Mendes Caquetti.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Chronic fatigue constitutes a cardinal manifestation of primary mitochondrial diseases and rare syndromes associated with structural bioenergetic dysfunction. Elamipretide, a mitochondria-targeting peptide with selective affinity for cardiolipin, was developed with the aim of stabilizing the inner mitochondrial membrane, optimizing the efficiency of the electron transport chain, and restoring ATP production. The present study aimed to evaluate, through a systematic review with quantitative meta-analysis of randomized clinical trials, the efficacy of elamipretide in reducing fatigue and improving functional capacity in adults with mitochondrial diseases associated with a chronic fatigue phenotype. Trials with a minimum duration of 12 weeks comparing elamipretide with placebo were included. The primary outcome consisted of the standardized mean difference in fatigue scales; secondary outcomes included the six-minute walk test, quality of life, and safety. Quantitative synthesis revealed a small-to-moderate effect on fatigue, without robust statistical significance in the aggregated population, although a greater magnitude was observed in Barth syndrome. Functional capacity demonstrated a favorable trend toward treatment, particularly in subgroups with structural cardiolipin defects. The safety profile was globally similar to placebo. It is concluded that elamipretide presents modest therapeutic potential in rare mitochondrial diseases, with consistent mechanistic plausibility, although the consolidation of evidence depends on additional trials with greater statistical power and longer follow-up.

Cite

APA

Caquetti, L. F. M. (2026). ELAMIPRETIDE AND CHRONIC FATIGUE SYMPTOMS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF TRIALS IN MITOCHONDRIAL DISEASES AND ITS TRANSLATIONAL RELEVANCE TO CHRONIC FATIGUE SYNDROME AND RELATED DISORDERS. INTERNATIONAL BLEST SCIENTIFIC, 1(03). https://doi.org/10.65671/ft79c689

Vancouver

Caquetti LFM. ELAMIPRETIDE AND CHRONIC FATIGUE SYMPTOMS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF TRIALS IN MITOCHONDRIAL DISEASES AND ITS TRANSLATIONAL RELEVANCE TO CHRONIC FATIGUE SYNDROME AND RELATED DISORDERS. INTERNATIONAL BLEST SCIENTIFIC. 2026;1(03). doi:10.65671/ft79c689

BibTeX
@article{Caquetti2026,
  author = {Caquetti, Luiz Felippe Mendes},
  title = {ELAMIPRETIDE AND CHRONIC FATIGUE SYMPTOMS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF TRIALS IN MITOCHONDRIAL DISEASES AND ITS TRANSLATIONAL RELEVANCE TO CHRONIC FATIGUE SYNDROME AND RELATED DISORDERS},
  journal = {INTERNATIONAL BLEST SCIENTIFIC},
  year = {2026},
  volume = {1},
  number = {03},
  doi = {10.65671/ft79c689}
}
Start for free →